title: An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
abstract: Recent data indicate that Bordetella pertussis can be an important cause of illness in adolescents and adults. In a randomized observer- and subject-blinded study, adults (> or = 18 years of age) received an acellular pertussis (aP) vaccine containing genetically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), or a saline placebo, and were monitored for safety and immunogenicity. IgG antibodies to PT, FHA, and PRN were measured by enzyme-linked immunosorbent assay (ELISA) and PT neutralization by a Chinese hamster ovary (CHO) cell assay. Local reactions, more common in the aP group, were mild and transient. One month after immunization, geometric mean ELISA antibody concentrations for the aP and placebo groups, respectively, were: anti-PT, 463 and 7.6; anti-FHA, 417 and 18; and anti-PRN, 855 and 14. The anti-PT neutralization titers for the aP and placebo groups were 1:3439 and 1:58 respectively. This aP vaccine is a safe and immunogenic candidate booster vaccine against pertussis for adults.
authors.affiliation: Pennridge Pediatric Associates, Sellersville, PA 18960, USA. erothstein@pol.net
authors.forename: E P
authors.initials: EP
authors.lastname: Rothstein
authors.forename: E L
authors.initials: EL
authors.lastname: Anderson
authors.forename: M D
authors.initials: MD
authors.lastname: Decker
authors.forename: G A
authors.initials: GA
authors.lastname: Poland
authors.forename: K S
authors.initials: KS
authors.lastname: Reisinger
authors.forename: M M
authors.initials: MM
authors.lastname: Blatter
authors.forename: R M
authors.initials: RM
authors.lastname: Jacobson
authors.forename: C A
authors.initials: CA
authors.lastname: Mink
authors.forename: D
authors.initials: D
authors.lastname: Gennevois
authors.forename: A E
authors.initials: AE
authors.lastname: Izu
authors.forename: F
authors.initials: F
authors.lastname: Sinangil
authors.forename: A G
authors.initials: AG
authors.lastname: Langenberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001886:Bordetella pertussis / Q000276:immunology; D016466:CHO Cells; D006224:Cricetinae; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D016297:Mutagenesis, Site-Directed; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000009:adverse effects* / Q000276:immunology*; D010919:Placebos; D011247:Pregnancy; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology; D010566:Virulence Factors, Bordetella / Q000235:genetics / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D010567:Pertussis Vaccine; D010919:Placebos; D015164:Vaccines, Inactivated; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin